Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Step surgery could spare High-Risk women from early menopause

NCT ID NCT06726330

Not yet recruiting Prevention Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ovaries are removed later, around menopause. The goal is to reduce cancer risk while delaying menopause and its side effects. About 1,100 women in France will choose either this new approach or the standard surgery, and they will be followed until age 70.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fimbriectomy followed by delayed oophorectomy (F-DO) surgical procedure
What this could lead to
If successful, this could offer a less drastic preventive option for women at high genetic risk of ovarian cancer, preserving ovarian function longer and delaying menopause.
What could go wrong
This is a non-randomized study, so results may be less definitive. The procedure is still being tested for effectiveness, and there is a small risk that cancer could still develop before the delayed ovary removal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinoma primary peritoneal carcinoma serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE SEROUS CARCINOMA PRIMARY PERITONEAL CARCINOMA PRIMARY PERITONEAL CARCINOMA STAGE III PRIMARY PERITONEAL CARCINOMA STAGE IV TUBO-OVARIAN CARCINOMA

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, France

  • Centre François Baclesse

    Caen, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Hospitalier Universitaire Dijon Bourgogne

    Dijon, France

  • Centre Hospitalier Universitaire de Lille

    Lille, France

  • Centre Hospitalier de Valenciennes

    Valenciennes, France, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Léon Bérard

    Lyon, France, France

  • Centre Oscar Lambret

    Lille, France

  • Centre hospitalier universitaire Grenoble-Alpes

    Grenoble, France

  • Clinique du Bois

    Lille, France

  • Gustave Roussy

    Paris, France

  • Hôpital Institut CURIE

    Paris, France

  • Hôpital Simone Veil - CH de Troyes

    Troyes, France

  • Hôpital Tenon AP-HP

    Paris, France

  • Hôpital de Saint-Cloud

    Saint-Cloud, France

  • Hôpital de la Pitié Salpêtrière - AP-HP

    Paris, France

  • Hôpitaux Privés Rouennais

    Rouen, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Godinot

    Reims, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut de cancérologie de l'Ouest Centre René GAUDUCHEAU

    Nantes, France

  • Institut universitaire du cancer de Toulouse

    Toulouse, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.